AtriCure, Inc. (ATRC)
28.80
+1.68
(+6.19%)
USD |
NASDAQ |
Jun 18, 16:00
28.80
0.00 (0.00%)
After-Hours: 20:00
AtriCure Research and Development Expense (Quarterly) : 23.50M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 23.50M |
| December 31, 2025 | 22.74M |
| September 30, 2025 | 22.13M |
| June 30, 2025 | 23.52M |
| March 31, 2025 | 21.77M |
| December 31, 2024 | 22.20M |
| September 30, 2024 | 20.20M |
| June 30, 2024 | 19.66M |
| March 31, 2024 | 19.84M |
| December 31, 2023 | 20.80M |
| September 30, 2023 | 20.35M |
| June 30, 2023 | 17.44M |
| March 31, 2023 | 15.33M |
| December 31, 2022 | 13.75M |
| September 30, 2022 | 15.17M |
| June 30, 2022 | 14.79M |
| March 31, 2022 | 13.63M |
| December 31, 2021 | 13.81M |
| September 30, 2021 | 11.28M |
| June 30, 2021 | 12.20M |
| March 31, 2021 | 11.22M |
| December 31, 2020 | 10.87M |
| September 30, 2020 | 10.58M |
| June 30, 2020 | 10.04M |
| March 31, 2020 | 11.59M |
| Date | Value |
|---|---|
| December 31, 2019 | 13.10M |
| September 30, 2019 | 10.15M |
| June 30, 2019 | 9.804M |
| March 31, 2019 | 8.176M |
| December 31, 2018 | 8.455M |
| September 30, 2018 | 8.556M |
| June 30, 2018 | 8.655M |
| March 31, 2018 | 9.057M |
| December 31, 2017 | 7.721M |
| September 30, 2017 | 7.966M |
| June 30, 2017 | 8.907M |
| March 31, 2017 | 9.55M |
| December 31, 2016 | 9.866M |
| September 30, 2016 | 8.271M |
| June 30, 2016 | 9.124M |
| March 31, 2016 | 8.563M |
| December 31, 2015 | 7.767M |
| September 30, 2015 | 6.504M |
| June 30, 2015 | 5.862M |
| March 31, 2015 | 5.609M |
| December 31, 2014 | 4.997M |
| September 30, 2014 | 5.033M |
| June 30, 2014 | 4.569M |
| March 31, 2014 | 4.001M |
| December 31, 2013 | 3.648M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 767.00M |
| Boston Scientific Corp. | 516.00M |
| AngioDynamics, Inc. | 7.084M |
| Alphatec Holdings, Inc. | 17.56M |
| Baxter International, Inc. | 124.00M |